Last $45.47 USD
Change Today -0.09 / -0.20%
Volume 341.1K
ALR On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Open
$45.50
Previous Close
$45.56
Day High
$45.65
Day Low
$45.06
52 Week High
02/27/15 - $45.65
52 Week Low
04/30/14 - $31.94
Market Cap
3.8B
Average Volume 10 Days
453.6K
EPS TTM
$-1.46
Shares Outstanding
83.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides point-of-care diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. Its Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of cardiology, infectious diseases, toxicology, diabetes, oncology, and women’s health, as well as offers connected device technologies. The company’s Health Information Solutions segment offers integrated programs and services focused on wellness, disease and condition management, productivity enhancement, and informatics. This segment’s health improvement programs comprise patient self-testing, condition and case management, women’s and children’s health, and health and wellness programs. Its Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis without antibiotics. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; health information solutions primarily to commercial and governmental health plans, self-insured employers, government and governmental programs, pharmaceutical companies, and physicians through sales force and channel partners; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

alere inc (ALR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2013.

alere inc (ALR) Key Developments

Alere Names Namal Nawana as CEO

Namal Nawana., 45, was named CEO of Alere, after two years as chief operating officer of the Waltham-based company.

Alere Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Tax Rate Guidance for the Year 2015

Alere Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company's net revenue was $666,857,000 compared to $673,155,000 a year ago. Operating income was $35,461,000 compared to $46,373,000 a year ago. Loss from continuing operations before benefit for income taxes was $20,428,000 compared to $9,920,000 a year ago. Loss from continuing operations was $21,471,000 or $0.32 per basic and diluted share compared to income from continuing operations of $1,367,000 or $0.06 per basic and diluted share a year ago. Net loss attributable to company and subsidiaries was $23,081,000 or $0.34 per basic and diluted share compared to $3,687,000 or $0.11 per basic and diluted share a year ago. Net loss available to common stockholders was $28,448,000 compared to $9,054,000 a year ago. Non-GAAP adjusted operating income was $131,257,000 compared to $134,729,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $59,223,000 or $0.66 per diluted share compared to $59,264,000 or $0.68 per diluted share a year ago. Non-GAAP adjusted net revenue was $667,142,000 compared to $673,625,000 a year ago. Non-GAAP adjusted provision for income taxes was $21,008,000 compared to $22,628,000 a year ago. Non-GAAP adjusted EBITDA from continuing operations for the fourth quarter of 2014 was $155.4 million, which reflects adjustments to add back non-interest related restructuring charges of $21.6 million, $0.2 million of acquisition-related costs and $5.8 million of costs associated with potential business dispositions. The year-over-year decrease in adjusted net revenue was primarily driven by the effects of foreign currency translation, which impacted adjusted net revenues by $16.5 million in the fourth quarter of 2014 and by a decrease in year-over-year royalties of $9.0 million. For the year, the company's net revenue was $2,586,690,000 compared to $2,619,862,000 a year ago. Operating income was $93,424,000 compared to $160,404,000 a year ago. Loss from continuing operations before benefit for income taxes was $118,500,000 compared to $106,201,000 a year ago. Loss from continuing operations was $167,713,000 or $2.28 per basic and diluted share compared to $53,399,000 or $0.92 per basic and diluted share a year ago. Net loss attributable to company and subsidiaries was $165,106,000 or $2.25 per basic and diluted share compared to $71,254,000 or $1.13 per basic and diluted share a year ago. Net loss available to common stockholders was $186,399,000 compared to $92,547,000 a year ago. Non-GAAP adjusted operating income was $452,581,000 compared to $518,317,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $178,032,000 or $2.07 per diluted share compared to $207,928,000 or $2.41 per diluted share a year ago. Non-GAAP adjusted net revenue was $2,588,091,682,000 compared to $2,622,102,000 a year ago. Non-GAAP adjusted provision for income taxes was $75,727,000 compared to $91,555,000 a year ago. On a last-twelve-months basis, non-GAAP adjusted EBITDA from continuing operations, with restructuring, acquisition and other costs added back, was $562.7 million. The company expects 2015 tax rate to be approximately 30%.

Alere Inc. to Report Q4, 2014 Results on Feb 10, 2015

Alere Inc. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Feb 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $45.47 USD -0.09

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $127.18 USD +8.18
BioMerieux €97.32 EUR +1.28
PerkinElmer Inc $47.00 USD 0.00
STERIS Corp $64.52 USD +0.23
West Pharmaceutical Services Inc $54.72 USD -0.23
View Industry Companies
 

Industry Analysis

ALR

Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.